Is Faes Farma (BME:FAE) A Bargain After Revenue Growth And Margin Pressure?

Faes Farma earnings: revenue up, margin under pressure

Faes Farma (BME:FAE) has just posted nine month 2026 results, showing higher sales and revenue alongside only a small uplift in net income, which puts the squeeze on the profit margin.

The business reported nine month sales of €551.94 million compared with €440.95 million a year earlier, and revenue of €563.54 million against €454 million, while net income was €74.13 million compared with €73.56 million.

Faes Farma’s latest update lands after a solid run in the share price, with a 7.22% 90 day share price return and a 6.75% gain over the past month, even though the year to date share price return is down 7.57%.

That pattern points to momentum rebuilding as investors weigh revenue growth against thinner margins. At the same time, the 10.57% 1 year total shareholder return and 76.49% 3 year total shareholder return indicate that longer term holders have still seen strong compounding despite the recent drag earlier in 2026.

Compare Faes Farma's margin pressure and recent share price momentum with a curated set of financially resilient peers through the 218 resilient stocks with low risk scores.

Faes Farma now trades at a sizeable discount to both analyst targets and estimated fair value after a sharp rebound in the share price. Is the market being cautious for good reason, or overly harsh on margin worries?

Most Popular Narrative: 9.9% Undervalued

Faes Farma’s most followed valuation narrative puts fair value at €5.36, which sits above the last close of €4.83 and frames the recent rebound as a move that still leaves a margin of safety on paper.

The integration of SIFI and Edol is adding ophthalmology as a new therapeutic platform, which expands Faes Farma's addressable market and can support a broader revenue base and scale benefits for EBITDA and earnings.

Latin America is becoming a core growth region for Faes Farma, with countries such as Mexico, Colombia and Central America showing double digit revenue increases, which can support higher consolidated revenue and potentially lift group operating margins as volumes build.

See why 3 investors see Faes Farma as 10% undervalued.

Result: Fair Value of €5.36 (UNDERVALUED)

Still, the story can change quickly if Bilastine erosion deepens or Latin America softens, since both are central supports for the current Faes Farma narrative.

Find out about the key risks to this Faes Farma narrative.

Next Steps

Mixed on Faes Farma after these results or leaning firmly bullish or cautious already? To stress test that early view against both sides of the argument, take a few minutes to weigh the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Faes Farma?

If Faes Farma has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that match different goals and risk levels.

• Hunt for misunderstood opportunities that combine quality with a potential valuation gap through the 204 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with robust payouts and resilient profiles via the 222 dividend fortresses.
• Prioritise capital protection by scanning financially sturdy businesses with balanced risk profiles using the list of solid balance sheet and fundamentals (199 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com